Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This is a phase 1 study of an anti-CD40 monoclonal antibody (2141-V11) in combination with
D2C7-IT for patients with recurrent World Health Organization (WHO) grade III or IV malignant
glioma at the Preston Robert Tisch Brain Tumor Center (PRTBTC) at Duke.